{'fraction_non_alphanumeric': 0.03343023255813953, 'fraction_numerical': 0.016715116279069766, 'mean_word_length': 5.495283018867925, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Resolvin E3 attenuates House Dust Mite (HDM) -induced asthmatic inflammation in a murine model

Background: Resolution of inflammation is an active process essential for tissue homeostasis. Resolvin E series are potent pro-resolving mediators of inflammation derived from the omega-3 fatty acid eicosapentaenoic acid (EPA). Resolvin E3 (RvE3) is a novel lipid mediator recently identified as a member of the Resolvin E series. Aims and Objects: We determined the impact of RvE3 on allergic airway inflammation using a murine model of asthma. Methods: Allergic airway inflammation was induced in BALB/c mice by House dust mite (HDM) sensitization and challenge (Day0-2,14-17). RvE3 was administrated intraperitoneally after the last HDM challenge(Day17,18). Leukocytes from the bronchoalveolar lavage fluid (BALF) were enumerated, and the lung tissue was used for pathological analysis and assessment of expression of cytokine in the lung. Lung resistance was measured and reported as the percent increase from baseline. Results: RvE3 treatment significantly reduced airway eosinophil recruitment, levels of Th2 cytokine (IL-5 and IL-13), and lung resistance to inhaled methacholine. RvE3 treatment improved airway hyper-responsiveness and airway inflammation. Conclusion: These findings provide evidence for RvE3 as a pivotal counterregulatory signal in allergic inflammation.